67 results
10-K/A
2023 FY
AURA
Aura Biosciences Inc
14 Jun 24
Annual report (amended)
4:37pm
Name and address of beneficial owner (1) | Shares Beneficially Owned | Percentage | |||||||||
> 5% Stockholders: | Matrix Capital Management Master Fund, LP (2) | 6,922,870 | 14.0 | % | |||||||
Eventide Asset Management, LLC (3) | 5,802,682 | 11.7 | % | ||||||||
Adage Capital Partners, L.P. (4) | 4,225,000 | 8.5 | % | ||||||||
Citadel-Multi Strategy Equities Master Fund Ltd. (5) | 3,631,494 | 7.3 | % | ||||||||
Entities affiliated with Medicxi (6) | 3,039,892 | 6.1 | % | ||||||||
Named Executive Officers and Directors: | Elisabet de los Pinos, Ph.D. (7) | 1,534,335 | 3.0 | % | |||||||
J. Jill Hopkins, M.D. (8) | — | * | |||||||||
Julie Feder (9) | 336,548 | * | |||||||||
David Johnson (10) | 722,634 | 1.5 | % | ||||||||
Giovanni Mariggi, Ph.D. | — | — | |||||||||
Raj Parekh, Ph.D. (11) | 32,000 | * | |||||||||
Sapna Srivastava, Ph.D. (12) | 72,243 | * | |||||||||
Karan Takhar | — | — | |||||||||
Antony Mattessich (13) | 66,658 | * | |||||||||
All executive officers and directors as a group (10 persons) (14) | 2,764,418 | 5.3 | % |
10-K/A
2023 FY
AURA
Aura Biosciences Inc
14 Jun 24
Annual report (amended)
4:37pm
The following table presents the compensation awarded to, earned by or paid to each of our named executive officers for the years indicated.
Year | Salary ($) | Bonus ($) | Stock Awards ($)(1) | Option Awards ($)(1) | Non-Equity Incentive Plan Compensation ($)(2) | All Other Compensation ($)(3) | Total ($) | ||||||||||||||||||||||||||||||||||
Elisabet de los Pinos, Ph.D. | 2023 | 585,525 | — | 1,240,688 | 1,400,963 | 289,835 | 19,800 | 3,536,811 | |||||||||||||||||||||||||||||||||
President, Chief Executive Officer and Director | 2022 | 555,000 | — | — | — | 222,000 | 18,300 | 795,300 | |||||||||||||||||||||||||||||||||
Julie B. Feder | 2023 | 437,825 | — | 496,275 | 560,385 | 166,374 | — | 1,660,859 | |||||||||||||||||||||||||||||||||
Chief Financial Officer | J. Jill Hopkins Chief Medical Officer and President of Research and Development | 2023 | 109,375 | 200,000 | (4) | 1,210,950 | 1,365,820 | 49,536 | — | 2,935,681 |
10-K/A
2023 FY
AURA
Aura Biosciences Inc
14 Jun 24
Annual report (amended)
4:37pm
The following table sets forth information regarding outstanding equity awards held by our named executive officers as of fiscal year 2023:
OPTION AWARDS (1) | STOCK AWARDS | |||||||||||||||||||||||||||
NAME | Grant Date | Number of Securities Underlying Unexercised Options Exercisable (#) | Number of Securities Underlying Unexercised Options Unexercisable (#) | Option Exercise Price ($) | Option Expiration Date | Number of Shares or Units of Stock That Have Not Vested (#) | Market Value of Shares or Units of Stock That Have Not Vested ($) | |||||||||||||||||||||
Elisabet de los Pinos | 1/19/2023 | — | — | — | — | 121,875 | (3) | 1,079,813 | ||||||||||||||||||||
1/19/2023 | — | 187,500 | (4) | 10.18 | 1/19/2033 | — | — | |||||||||||||||||||||
10/28/2021 | — | — | — | — | 37,178 | (5) | 329,397 | |||||||||||||||||||||
10/28/2021 | 172,656 | 146,094 | (6) | 14.00 | 10/28/2031 | — | — | |||||||||||||||||||||
6/28/2021 | 387,779 | 232,658 | (7) | 5.48 | 6/28/2031 | — | — | |||||||||||||||||||||
3/16/2020 | 186,769 | 8,120 | (8) | 4.25 | 3/16/2030 | — | — | |||||||||||||||||||||
2/6/2019 | 63,548 | — | 3.16 | 2/6/2029 | — | — | ||||||||||||||||||||||
2/21/2018 | 364,963 | — | 2.74 | 2/21/2028 | — | — | ||||||||||||||||||||||
7/7/2017 | 14,598 | — | 5.21 | 7/7/2027 | — | — | ||||||||||||||||||||||
4/11/2016 | 14,598 | — | 5.48 | 4/11/2026 | — | — | ||||||||||||||||||||||
6/2/2015 | 10,948 | — | 5.07 | 6/2/2025 | — | — | ||||||||||||||||||||||
10/1/2014 | 5,474 | — | 5.76 | 10/1/2024 | — | — | ||||||||||||||||||||||
Julie Feder | 1/19/2023 | — | — | — | — | 48,750 | (3) | 431,925 | ||||||||||||||||||||
1/19/2023 | — | 75,000 | (4) | 10.18 | 1/19/2033 | — | — | |||||||||||||||||||||
10/28/2021 | — | — | — | — | 13,124 | (5) | 116,279 | |||||||||||||||||||||
10/28/2021 | 60,937 | 51,563 | (6) | 14.00 | 10/28/2031 | — | — | |||||||||||||||||||||
6/28/2021 | 78,471 | 47,076 | (7) | 5.48 | 6/28/2031 | — | — | |||||||||||||||||||||
3/16/2020 | 33,534 | 1,457 | (8) | 4.25 | 3/16/2030 | — | — | |||||||||||||||||||||
2/6/2019 | 18,248 | — | 3.16 | 2/6/2029 | — | — | ||||||||||||||||||||||
10/3/2018 | 85,757 | — | 2.74 | 10/3/2028 | — | — | ||||||||||||||||||||||
J. Jill Hopkins, M.D. | 11/1/2023 | — | — | — | — | 135,000 | (10) | 1,196,100 | ||||||||||||||||||||
11/1/2023 | — | 200,000 | (9) | 8.97 | 11/1/2033 | — | — |
10-K/A
2023 FY
AURA
Aura Biosciences Inc
14 Jun 24
Annual report (amended)
4:37pm
Our non-employee directors are compensated pursuant to a formal policy pursuant to which we pay our non-employee directors a cash retainer for service on our Board and for service on each committee on which the director is a member. The Chair of each committee receives a higher retainer for such service. The fees paid to non-employee directors for service on our Board and for service on each committee of our Board on which the director is a member are as follows:
Board of Directors: | Members | $ | 40,000 | |||
Annual retainer for non-executive chair | $ | 30,000 | ||||
Audit Committee: | Members (other than chair) | $ | 7,500 | |||
Retainer for chair | $ | 15,000 | ||||
Compensation Committee: | Members (other than chair) | $ | 5,000 | |||
Retainer for chair | $ | 10,000 | ||||
Nominating and Corporate Governance Committee: | Members (other than chair) | $ | 4,000 | |||
Retainer for chair | $ | 8,000 |
10-K/A
2023 FY
AURA
Aura Biosciences Inc
14 Jun 24
Annual report (amended)
4:37pm
The following table provides information as of December 31, 2023 with respect to the shares of our common stock that may be issued under our existing equity compensation plans.
Plan Category | Number of securities to be issued upon exercise of outstanding options, warrants and rights (#) (a) | Weighted- average exercise price of outstanding options, warrants and rights ($) (b) | Number of securities remaining available for issuance under equity compensation plans (excluding securities reflected in column (a)) (#) (c) | |||||||||
Equity compensation plans approved by security holders(1) | 6,123,753 | (2) | 8.46 | (2) | 6,946,623 | (3) | ||||||
Equity compensation plans not approved by security holders | — | — | — | |||||||||
Total | 6,123,753 | 8.46 | 6,946,623 | |||||||||
10-K/A
kbs7u raclwyk
14 Jun 24
Annual report (amended)
4:37pm
10-K/A
ghwz4epdck2wsz
14 Jun 24
Annual report (amended)
4:37pm
10-K/A
e5j 7y9v8uzpfpty
14 Jun 24
Annual report (amended)
4:37pm